BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» ChanRx Closes Series A to Advance Atrial Fib Drug
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ChanRx Closes Series A to Advance Atrial Fib Drug
Nov. 23, 2011
By
Marie Powers
No Comments
ChanRx Corp., launched in 2006 as a spinoff from Cleveland-based pharmaceutical testing company ChanTest Corp., closed a Series A financing with investments from Sante Ventures, of Austin, Texas, and company founder and chairman Arthur "Buzz" Brown.
BioWorld